FLUOXETINE AS A NOVEL TREATMENT TO ATTENUATE CISPLATIN-INDUCED COGNITIVE IMPAIRMENT

<p>Cisplatin, a chemotherapeutic agent, initiates cell death through various methods that include mtDNA damage during cell replication and produces damaging pro-inflammatory cytokines. This can result in long-term chemotherapy-related cognitive impairment (CRCI). Fluoxetine (FLX) is a selective serotonin reuptake inhibitor widely used in patients with anxiety and mood disorders. Published studies report that FLX could sensitize cancer cells to chemotherapy treatment and assist in attenuating CRCI. The aim of this study was to assess the ability of FLX to sensitize cancer cells to cisplatin treatment as well as the ability to attenuate cisplatin-induced cognitive impairment. Combined treatment of cisplatin +FLX was able to sensitize different cancer cell lines to treatment with cisplatin. In addition, mice treated with FLX performed significantly better when considering the response accuracy of the last three trials, regardless of criteria. These results suggest that FLX could have had a positive effect on the level of task difficulty and could improve working memory in mice.</p>

Name thesis:degree_name

Master of Science

Level thesis:degree_level

Thesis

Discipline thesis:degree_discipline

Psychological Science

Year dc:date.available

2021

Author dc:creator

• Delgado, Xochitl

Contributors dc:contributor

• Amber Lacrosse

• chemotherapy
• cognition
• cancer
• cell culture
• working memory
• cognitive flexibility
• fluoxetine
• cisplatin
• Behavioral Neurobiology
• Biological Psychology
• Molecular and Cellular Neuroscience

Repository record dc:identifier

https://commons.nmu.edu/theses/688

OAI identifier oai:identifier

oai:commons.nmu.edu:theses-1725